Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: Autologous CD8+ SLC45A2-specific T Lymphocytes
DRUG: Cyclophosphamide
BIOLOGICAL: Ipilimumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]